80 related articles for article (PubMed ID: 3309762)
21. Docetaxel: new preparation. No first-line use in metastatic breast cancer.
Prescrire Int; 2001 Dec; 10(56):178-9. PubMed ID: 11824441
[TBL] [Abstract][Full Text] [Related]
22. Randomized, controlled trial investigating short-term health-related quality of life with doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: European Organization for Research and Treatment of Cancer Breast Cancer Group, Investigational Drug Branch for Breast Cancer and the New Drug Development Group Study.
Bottomley A; Biganzoli L; Cufer T; Coleman RE; Coens C; Efficace F; Calvert HA; Gamucci T; Twelves C; Fargeot P; Piccart M;
J Clin Oncol; 2004 Jul; 22(13):2576-86. PubMed ID: 15226325
[TBL] [Abstract][Full Text] [Related]
23. Randomized parallel study of doxorubicin plus paclitaxel and doxorubicin plus cyclophosphamide as neoadjuvant treatment of patients with breast cancer.
Diéras V; Fumoleau P; Romieu G; Tubiana-Hulin M; Namer M; Mauriac L; Guastalla JP; Pujade-Lauraine E; Kerbrat P; Maillart P; Pénault-Llorca F; Buyse M; Pouillart P
J Clin Oncol; 2004 Dec; 22(24):4958-65. PubMed ID: 15611510
[TBL] [Abstract][Full Text] [Related]
24. Ineffectiveness of adjuvant chemotherapy using DTIC and cyclophosphamide in patients with resectable metastatic melanoma.
Balch CM; Murray D; Presant C; Bartolucci AA
Surgery; 1984 Apr; 95(4):454-9. PubMed ID: 6369594
[TBL] [Abstract][Full Text] [Related]
25. [Results of 2 chemotherapy protocols (VPA and C-VPA) in acute adult lymphoblastic leukemia].
Avilés Miranda A; Ambriz Fernández R; Díaz Maqueo JC; Mascaró Sacristán J; Sinco Angeles A; Pizzuto J
Rev Invest Clin; 1983; 35(4):285-9. PubMed ID: 6369467
[No Abstract] [Full Text] [Related]
26. Clinical predictors of chemotherapy-induced nausea and vomiting in breast cancer patients receiving adjuvant doxorubicin and cyclophosphamide.
Shih V; Wan HS; Chan A
Ann Pharmacother; 2009 Mar; 43(3):444-52. PubMed ID: 19193584
[TBL] [Abstract][Full Text] [Related]
27. [Specific immunotherapy in metastasizing breast cancer combined with chemotherapy. A prospective randomized study].
Graninger W; Bettelheim P; Jakesz R; Rainer H; Moser K; Mörz R; Miksche M
Acta Med Austriaca Suppl; 1979; 6():322-4. PubMed ID: 299220
[TBL] [Abstract][Full Text] [Related]
28. Biology of residual breast cancer after therapy: a kinetic interpretation.
Norton L
Prog Clin Biol Res; 1990; 354A():109-32. PubMed ID: 2247484
[No Abstract] [Full Text] [Related]
29. Adjuvant intermittent chemoimmunotherapy for primary breast cancer: a prospective study with immunologic follow-up.
Betzler M; Schreml W; Lang M; Lohrmann HP; Flad HD; Schlag P; Herfarth C; Heimpel H
Recent Results Cancer Res; 1982; 80():185-91. PubMed ID: 7036282
[TBL] [Abstract][Full Text] [Related]
30. [Randomized study: chemotherapy versus chemotherapy plus transfer factor in metastasized breast neoplasm].
Rainer H; Moser K; Bettelheim P
Verh Dtsch Ges Inn Med; 1978; (84):604-6. PubMed ID: 742083
[No Abstract] [Full Text] [Related]
31. Chemotherapy for prostatic carcinoma.
Eisenberger MA; Abrams JS
Semin Urol; 1988 Nov; 6(4):303-10. PubMed ID: 3068768
[No Abstract] [Full Text] [Related]
32. Implications of survival curve slopes on the interpretation of adjuvant therapy results.
Eriguchi M; Mathé G
Suppl J Med Oncol Tumor Pharmacother; 1988; 1():93-7. PubMed ID: 3074230
[No Abstract] [Full Text] [Related]
33. Immunotherapy for breast cancer: is it feasible?
Clarke E
Immunotherapy; 2015; 7(11):1135-43. PubMed ID: 26567869
[No Abstract] [Full Text] [Related]
34. Activities of the EORTC Breast Cancer Co-operative Group: an overview. [European Organization for Research and Treatment of Cancer].
Wildiers J; Vantongelen K; van Dongen JA; Rotmensz N; Sylvester R
Eur J Cancer Clin Oncol; 1988 Jan; 24(1):3-8. PubMed ID: 3276532
[No Abstract] [Full Text] [Related]
35. Chemotherapy and hormonal therapy in combination.
Hug V; Thames H; Clark J
J Clin Oncol; 1988 Jan; 6(1):173-7. PubMed ID: 3275747
[TBL] [Abstract][Full Text] [Related]
36. Randomized trials in rare tumors.
Omura GA
J Clin Oncol; 1986 Feb; 4(2):262-3. PubMed ID: 3511186
[No Abstract] [Full Text] [Related]
37. Has adjuvant treatment of breast cancer had an unfair trial?
Mittra I
BMJ; 1990 Dec; 301(6764):1317-9. PubMed ID: 2271858
[No Abstract] [Full Text] [Related]
38. Do we need a new strategy to treat metastatic breast cancer?
Bertino JR; O'Connor OA
Curr Oncol Rep; 1999; 1(2):85-7. PubMed ID: 11122803
[No Abstract] [Full Text] [Related]
39. A randomized comparative study of prednimustine and doxorubicin in patients with metastatic breast cancer.
Allegra JC
Semin Oncol; 1986 Mar; 13(1 Suppl 1):42-4. PubMed ID: 3513319
[TBL] [Abstract][Full Text] [Related]
40. Update on cancer therapy.
Loh KK
Hawaii Med J; 1988 Aug; 47(8):376. PubMed ID: 3049448
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
